Seeing Through Drug Price Transparency

By PCMA, Special for  USDR


As part of its campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video, “What is drug price transparency?” explaining how transparency is widely used in the prescription drug marketplace for patients and employers, and highlighting that “the wrong kind” of transparency can “backfire” by reducing competition and resulting in higher drug  prices.

Click here to watch the new  video.

“The right kind of transparency is important for both patients and payers,” said PCMA President and CEO Mark Merritt. “But according to the Federal Trade Commission, the wrong kind of transparency would hurt consumers by giving drug companies inside information that could help them collude with their competitors and charge higher  prices.”

As the new Administration and Congress explore ways to reduce prescription drug costs, PCMA recently launched a campaign highlighting how pharmacy benefit managers (PBMs) protect consumers, employers, and government programs from high drug  prices.

The campaign’s website – – is a platform explaining how PBMs reduce costs and how greater reliance on competition and PBM tools generate significant savings for public and private health care  programs.

PCMA is the national association representing America’s pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and  others.

SOURCE Pharmaceutical Care Management  Association

All opinions expressed on USDR are those of the author and not necessarily those of US Daily Review.